Comparing two bone medicines after stopping denosumab
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who has gone through menopause and are between 50 and 85 years old.
- Your bone density T-score is between -1.5 and -3.0 (this means your bones are thinning but not severely yet).
- You have been getting denosumab (Prolia) shots every 6 months for at least a year, but for less than 3 years total (3 to 5 doses).
- You haven't had any broken bones due to osteoporosis in the last 12 months.
- You haven't recently taken any other osteoporosis medicines, and you have no history of allergy to bisphosphonates (a class of bone drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
This trial tests if it's safe to switch from a long-term osteoporosis medication called Prolia to another treatment. It may help women and men who have been on Prolia for at least 3 years.
This trial compares two osteoporosis drugs (romosozumab and denosumab) given alone or together to see which works better for improving bone density. It may help if you are a postmenopausal woman with osteoporosis and have not taken strong bone medications recently.
This trial tests whether giving zoledronic acid (a bone-strengthening infusion) right after stopping denosumab can help prevent bone loss in women with post-menopausal osteoporosis. It may be a good option if you have finished at least 2 years of denosumab and your doctor says it's safe to stop.
This study tests a new form of calcium (amorphous calcium carbonate) to see if it can improve bone density in postmenopausal women with osteoporosis. It may offer an alternative for women who cannot or choose not to take other osteoporosis medications.
This Phase 2 study tests whether zoledronic acid or denosumab can prevent bone thinning in critically ill adults after staying in the ICU. It may help reduce the risk of future bone fractures if your body is at higher risk during and after critical illness.
Hear when a new Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.